• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION, ASHITAKA CAPIOX CUSTOM PACK; OXYGENATOR, CARDIOPULMONARY BYPASS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION, ASHITAKA CAPIOX CUSTOM PACK; OXYGENATOR, CARDIOPULMONARY BYPASS Back to Search Results
Model Number N/A
Device Problem Decrease in Pressure (1490)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 07/06/2023
Event Type  malfunction  
Event Description
The user facility reported that it was an emergency case, mera oxygenator of mera l-circuit was used initially.As the oxygenation performance decreased, around 4:15, fx15 only from xry39001 circuit was used to perform ecc.Afterward, the performance of fx15 decreased also.After pumping, they proceeded to pcps, however, though the performance was improved somewhat when the patient was cooled, overall gas exchange performance was poor for both mera and fx15.It was an emergency case, the patient's tg was about 3700, and the blood inside the circuit seemed white possibly due to fat.The procedure outcome was not reported.The patient was not harmed.
 
Manufacturer Narrative
A1: patient identifier: requested, not provided.A2: age & date of birth: requested, not provided.A3: patient sex: requested, not provided.A4: weight: requested, not provided.A5: ethnicity: requested, not provided.A6: race: requested, not provided.D4: udi: n/a as this product is not exported to the us market.D6a: implanted date: requested, not provided.D6b: explanted date: requested, not provided.E3: occupation: clinical engineer.G4: pma/510(k) - k130520.1.Inspection of the actual sample: 1.1.Visual inspection of the actual sample upon receipt found no anomaly such as a breakage.1.2.The actual sample was filled with glutaraldehyde-containing saline solution and fixed, the housing and filter were removed, and visual inspection of the gas transfer part was performed.No anomaly was found in the condition of fiber winding.White adherents were found on the removed filter.1.3.The fiber layer was removed gradually, and visual inspection of the gas transfer part was performed.No anomaly was found in the condition of fiber winding.1.4.The heat exchanger was removed from the outer cylinder and subjected to visual and magnifying inspection.White adherents were found.No deformation or other anomaly that could lead to an obstruction was found in the heat exchanger.2.Review of pump record: it was confirmed that extracorporeal circulation started at 23:44.An arrow was written in the pump record just after 4:14, in addition, from the information that the mera oxygenator was exchanged with fx15 at 4:15, it was thought that the exchange of oxygenator was done at this time.Po2 recorded at around 4:34, after exchanging mera with fx15, was 261mmhg.The circulation conditions at this time could not be read from the pump record.A second arrow was written around 5:09, and pcps was also written below it, so it was thought that pcps was introduced at this time.3.History investigation: 3.1.Review of the manufacturing record and the shipping inspection record of the actual sample found no anomaly.3.2.Review of the past complaint file found no other similar report on the involved product code/lot number.3.3.Manufacturing date: november 29, 2022.4.Cause of occurrence/conclusion: during the investigation, white adherents were found inside the actual sample.Though the white adherents were found, as for the cause of occurrence, the causal relation between the white adherents and the poor gas transfer performance was not clarified.In addition, it was not possible to clarify its properties from the results of the investigation.Relevant ifu reference: "measure blood gases and make necessary adjustments as follows.A.Control pao2 by changing concentration of oxygen in ventilating gas using gas blender.To decrease pao2, decrease fio2.To increase pao2, increase fio2.B.Control paco2 by changing the total gas flow.To decrease paco2, increase total gas flow.To increase paco2, decrease total gas flow." terumo medical products (tmp) (importer) registration no.2243441 is submitting this report on behalf of ashitaka factory of terumo corporation (manufacturer) registration no.(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CAPIOX CUSTOM PACK
Type of Device
OXYGENATOR, CARDIOPULMONARY BYPASS
Manufacturer (Section D)
TERUMO CORPORATION, ASHITAKA
150 maimaigi-cho
fujinomiya city, 418
JA  418
Manufacturer (Section G)
TERUMO CORPORATION, ASHITAKA
reg. no. 9681834
150 maimaigi-cho
fujinomiya city, 418
JA   418
Manufacturer Contact
gina digioia
265 davidson ave
suite 320
somerset, NJ 08873
6402040886
MDR Report Key17465651
MDR Text Key321112585
Report Number9681834-2023-00156
Device Sequence Number1
Product Code DTZ
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
K071494
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility,Company Representative
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 08/04/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/04/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberN/A
Device Catalogue NumberCX-XRY39001
Device Lot Number221129
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer07/11/2023
Is the Reporter a Health Professional? Yes
Date Manufacturer Received07/07/2023
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured11/29/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
CDI; S5
-
-